Anscheinend verwenden Sie einen älteren Internet Explorer. Leider unterstützen wir, genau wie Microsoft, diesen Browser nicht mehr. Sie werden also Fehlermeldungen und ein inkonsistentes Design erleben.
Bitte haben Sie Verständnis und entschuldigen Sie die Unannehmlichkeiten.
toggle menu

Isarna Therapeutics

Isarna Therapeutics, a privately held clinical stage biopharmaceutical company, has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic and fibrotic diseases and fight cancer.

The company advances a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Isarna Therapeutics has accumulated a vast amount of expertise and intellectual property by focusing its research and development efforts on targeting the transforming growth factor beta (TGF-β) pathway in high-medical-need diseases. The privately held, clinical stage biopharmaceutical company Isarna is established in the Netherlands, Germany (Munich), and the United States.

The company has developed a portfolio of compounds (antisense oligonucleotides) specifically designed to target the three different TGF-β isoforms (TGF-β1, TGF-β2, and TGF-β3) for the treatment of ophthalmic and fibrotic diseases and cancer. This expertise is unique in the world.

Bayern Kapital Website Isarna-revised PC 09.07.15

Bayern Kapital Website Isarna-revised PC 09.07.16

Bayern Kapital Website Isarna-revised PC 09.07.17